Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab - 01/11/17
, Helena Polena b, c, d, Barry Stidder b, c, d, Abir Khalil-Mgharbel b, c, d, Estelle Houivet g, Thierry Lequerré a, Patrice Fardellone e, Xavier Le-Loët a, Peggy Philippe f, Christian Marcelli h, Olivier Vittecoq a, 1, Isabelle Vilgrain b, c, d, 1Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
The aim of this study was to investigate the clinical value of sVE and anti-vascular endothelial-cadherin antibodies (AAVE) in RA treated with etanercept or adalimumab combined with methotrexate.
Methods |
This was an 18-month prospective multicenter study in which patients had active RA, requiring TNF antagonist. sVE rates and AAVE titers were measured respectively by dot blot and ELISA. The relationship of these biomarkers with parameters reflecting articular or systemic disease activity, progression of structural damage, and response or remission to treatment was analyzed.
Results |
Forty-eight patients received TNF blocking agents. Variation of sVE rates were significantly correlated with that of C-reactive protein (CRP) levels at weeks 6, 12, 26 and 52. A significant decrease in sVE levels was observed in the group of patients exhibiting a decrease in CRP levels as compared to the patient group with unmodified CRP. AAVE at baseline were correlated with rheumatoid factor. Kinetics analysis of sVE levels and AAVE titers showed that their level were not associated with disease activity score and to methotrexate/adalimumab or etanercept response.
Conclusions |
sVE is a biomarker associated with systemic RA activity under anti-TNF. AAVE are related to autoantibodies usually associated to RA.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Soluble VE cadherin, Anti-vascular endothelial-cadherin antibody, Etanercept, Adalimumab
Plan
Vol 84 - N° 6
P. 685-691 - décembre 2017 Retour au numéro
Article précédent
- Pathophysiology of bone metastases from solid malignancies
- Philippe Clézardin
- Translation and adaptation of the French version of the Heart Disease Fact Questionnaire – Rheumatoid Arthritis (HDFQ-RA 1&2)
- Thomas Frayssac, Françoise Fayet, Malory Rodere, Carine Savel, Martin Soubrier, Bruno Pereira
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?